After hours: March 17 at 6:01:05 PM EDT ...

Nektar Therapeutics (NKTR) came out with quarterly earnings of $0.15 per share, beating the Zacks Consensus Estimate of a loss of $0.13 per share. This compares to loss of $0.22 per share a year ago.

In a report released today, Yasmeen Rahimi from Piper Sandler maintained a Buy rating on Nektar Therapeutics (NKTR – Research Report), with a price target of $7.00. The company’s shares closed ...

Oppenheimer upgraded Nektar (NKTR) to Outperform from Perform with a $6 price target Easily identify stocks' risks and opportunities. Discover stocks' market position with detailed competitor ...

SAN FRANCISCO (AP) — SAN FRANCISCO (AP) — Nektar Therapeutics (NKTR) on Wednesday reported fourth-quarter earnings of $7.3 million. The San Francisco-based company said it had net income of 3 ...

Good day, and thank you for standing by. Welcome to the Nektar Therapeutics Fourth Quarter 2024 financial results conference call. At this time, all participants are in a listen-only mode.

(RTTNews) - Below are the earnings highlights for Nektar Therapeutics (NKTR): Earnings: $7.26 million in Q4 vs. -$42.08 million in the same period last year. EPS: $0.03 in Q4 vs. -$0.22 in the ...

Nektar Therapeutics (NKTR) reported its Q4 2024 earnings, surpassing analysts’ expectations with an earnings per share (EPS) of $0.03, compared to the forecasted loss of $0.16. The company’s ...

With Takeda’s £46 billion acquisition of Shire, it’s been a busy year for pharma M&A – and according to analysts Datamonitor, the specialist biotechs Nektar, BioMarin and Alnylam are the ...